Edwards Lifesciences Corp
EW76.280USD
+0.739+0.98%
Fechamento 04/29, 16:00（ET）Cotações atrasadas em 15 min
44.90BValor de mercado
10.76P/L TTM
Mais detalhes de Edwards Lifesciences Corp Empresa
Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
Informações da empresa
Código da empresaEW
Nome da EmpresaEdwards Lifesciences Corp
Data de listagemMar 27, 2000
Fundado em1999
CEOMr. Bernard J. Zovighian
Número de funcionários15800
Tipo de títulosOrdinary Share
Fim do ano fiscalMar 27
EndereçoOne Edwards Way
CidadeIRVINE
Bolsa de valoresNYSE Consolidated
PaísUnited States of America
Código postal92614
Telefone19492502500
Sitehttps://www.edwards.com
Código da empresaEW
Data de listagemMar 27, 2000
Fundado em1999
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Scott B. Ullem
Mr. Scott B. Ullem
Chief Financial Officer, Corporate Vice President
Chief Financial Officer, Corporate Vice President
273.31K
--
Mr. Larry L. Wood
Mr. Larry L. Wood
Corporate Vice President, Group President - Transcatheter Aortic Valve Replacement (TAVR) and Surgical Structural Heart
Corporate Vice President, Group President - Transcatheter Aortic Valve Replacement (TAVR) and Surgical Structural Heart
178.00K
-0.19%
Mr. Steven R. (Steve) Loranger
Mr. Steven R. (Steve) Loranger
Independent Director
Independent Director
71.32K
--
Mr. Daniel J. Lippis
Mr. Daniel J. Lippis
Corporate Vice President - JAPAC (Japan, Greater China and Asia Pacific)
Corporate Vice President - JAPAC (Japan, Greater China and Asia Pacific)
22.23K
--
Mr. Bernard J. Zovighian
Mr. Bernard J. Zovighian
Chief Executive Officer, Director
Chief Executive Officer, Director
17.95K
--
Mr. Daveen Chopra
Mr. Daveen Chopra
Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
13.29K
-51.80%
Mr. Paul A. Laviolette
Mr. Paul A. Laviolette
Independent Director
Independent Director
7.72K
-3.16%
Dr. David T. Feinberg, M.D.
Dr. David T. Feinberg, M.D.
Independent Director
Independent Director
2.31K
--
Mr. Nicholas J. (Nick) Valeriani
Mr. Nicholas J. (Nick) Valeriani
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Kieran T. Gallahue
Mr. Kieran T. Gallahue
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Scott B. Ullem
Mr. Scott B. Ullem
Chief Financial Officer, Corporate Vice President
Chief Financial Officer, Corporate Vice President
273.31K
--
Mr. Larry L. Wood
Mr. Larry L. Wood
Corporate Vice President, Group President - Transcatheter Aortic Valve Replacement (TAVR) and Surgical Structural Heart
Corporate Vice President, Group President - Transcatheter Aortic Valve Replacement (TAVR) and Surgical Structural Heart
178.00K
-0.19%
Mr. Steven R. (Steve) Loranger
Mr. Steven R. (Steve) Loranger
Independent Director
Independent Director
71.32K
--
Mr. Daniel J. Lippis
Mr. Daniel J. Lippis
Corporate Vice President - JAPAC (Japan, Greater China and Asia Pacific)
Corporate Vice President - JAPAC (Japan, Greater China and Asia Pacific)
22.23K
--
Mr. Bernard J. Zovighian
Mr. Bernard J. Zovighian
Chief Executive Officer, Director
Chief Executive Officer, Director
17.95K
--
Mr. Daveen Chopra
Mr. Daveen Chopra
Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
13.29K
-51.80%
Detalhamento da receita
Moeda: USDTempo de atualização: dom, 6 de abr
Moeda: USDTempo de atualização: dom, 6 de abr
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
FY2015
Por EmpresaUSD
Nome
Receita
Proporção
Transcatheter Aortic Valve Replacement
4.11B
75.49%
Surgical Heart Valve Therapy
981.30M
18.04%
Transcatheter Mitral and Tricuspid Therapies
352.10M
6.47%
Por RegiãoUSD
Nome
Receita
Proporção
United States
3.21B
58.94%
Europe
1.32B
24.30%
Rest of the world
572.00M
10.52%
Japan
339.80M
6.25%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Transcatheter Aortic Valve Replacement
4.11B
75.49%
Surgical Heart Valve Therapy
981.30M
18.04%
Transcatheter Mitral and Tricuspid Therapies
352.10M
6.47%
Acionista
Tempo de atualização: qua, 16 de abr
Tempo de atualização: qua, 16 de abr
Estatísticas dos acionistas
Tipo
Estatísticas dos acionistas
Acionista
Proporção
The Vanguard Group, Inc.
11.71%
Wellington Management Company, LLP
5.65%
BlackRock Institutional Trust Company, N.A.
5.40%
State Street Global Advisors (US)
4.39%
Geode Capital Management, L.L.C.
2.32%
Other
70.53%
Estatísticas dos acionistas
Acionista
Proporção
The Vanguard Group, Inc.
11.71%
Wellington Management Company, LLP
5.65%
BlackRock Institutional Trust Company, N.A.
5.40%
State Street Global Advisors (US)
4.39%
Geode Capital Management, L.L.C.
2.32%
Other
70.53%
Tipo
Acionista
Proporção
Investment Advisor/Hedge Fund
44.56%
Investment Advisor
31.04%
Hedge Fund
3.82%
Pension Fund
2.38%
Research Firm
2.13%
Bank and Trust
1.79%
Sovereign Wealth Fund
1.50%
Individual Investor
0.89%
Endowment Fund
0.82%
Other
11.08%
Participação acionária institucional
Tempo de atualização: dom, 19 de jan
Tempo de atualização: dom, 19 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q1
2552
530.96M
90.30%
-2.24M
2024Q4
2597
531.64M
90.42%
-4.10M
2024Q3
2568
511.38M
84.93%
-20.94M
2024Q2
2559
522.19M
86.68%
-12.58M
2024Q1
2572
518.82M
86.18%
-12.08M
2023Q4
2573
509.93M
84.08%
-27.42M
2023Q3
2530
522.96M
86.03%
-18.75M
2023Q2
2517
523.54M
86.35%
-20.02M
2023Q1
2495
522.98M
86.26%
-32.79M
2022Q4
2485
532.76M
86.16%
-12.94M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
The Vanguard Group, Inc.
68.87M
11.71%
+6.55M
+10.50%
Dec 31, 2024
Wellington Management Company, LLP
33.21M
5.65%
+1.68M
+5.32%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
31.74M
5.4%
-1.09M
-3.33%
Dec 31, 2024
State Street Global Advisors (US)
25.81M
4.39%
-457.01K
-1.74%
Dec 31, 2024
Geode Capital Management, L.L.C.
13.65M
2.32%
+126.19K
+0.93%
Dec 31, 2024
JP Morgan Asset Management
10.76M
1.83%
+6.05M
+128.20%
Dec 31, 2024
Fisher Investments
9.78M
1.66%
+696.97K
+7.68%
Dec 31, 2024
Citadel Advisors LLC
9.42M
1.6%
+7.43M
+372.91%
Dec 31, 2024
Walter Scott & Partners Ltd.
9.41M
1.6%
-720.79K
-7.12%
Dec 31, 2024
Norges Bank Investment Management (NBIM)
8.25M
1.4%
-285.79K
-3.35%
Dec 31, 2024
Ver Mais
ETFs Relacionados
Tempo de atualização: dom, 6 de abr
Tempo de atualização: dom, 6 de abr
Nome
Proporção
iShares U.S. Medical Devices ETF
4.32%
Future Fund Long/Short ETF
3.05%
Global X Aging Population ETF
2.15%
Themes US R&D Champions ETF
1.97%
Tema Cardiovascular and Metabolic ETF
1.77%
iShares Health Innovation Active ETF
1.67%
SPDR S&P Health Care Equipment ETF
1.61%
ROBO Global Healthcare Technology & Innovation ETF
1.56%
Invesco S&P 500 Equal Weight Health Care ETF
1.54%
First Trust Indxx Medical Devices ETF
1.41%
Ver Mais
iShares U.S. Medical Devices ETF
Proporção4.32%
Future Fund Long/Short ETF
Proporção3.05%
Global X Aging Population ETF
Proporção2.15%
Themes US R&D Champions ETF
Proporção1.97%
Tema Cardiovascular and Metabolic ETF
Proporção1.77%
iShares Health Innovation Active ETF
Proporção1.67%
SPDR S&P Health Care Equipment ETF
Proporção1.61%
ROBO Global Healthcare Technology & Innovation ETF
Proporção1.56%
Invesco S&P 500 Equal Weight Health Care ETF
Proporção1.54%
First Trust Indxx Medical Devices ETF
Proporção1.41%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
May 07, 2020
Split
1>3
Data
Tipo
Proporção
May 07, 2020
Split
1>3